Subtopic Deep Dive
CDK4/6 Inhibitors in Hormone Receptor-Positive Breast Cancer
Research Guide
What is CDK4/6 Inhibitors in Hormone Receptor-Positive Breast Cancer?
CDK4/6 inhibitors are selective small-molecule drugs targeting cyclin-dependent kinases 4 and 6, combined with endocrine therapy to treat hormone receptor-positive, HER2-negative advanced breast cancer by halting cell cycle progression.
Palbociclib, ribociclib, and abemaciclib represent the primary CDK4/6 inhibitors approved for first- and second-line therapy in HR+/HER2- advanced breast cancer. Clinical trials such as MONALEESA-2 (Hortobágyi et al., 2016, 1897 citations) and PALOMA-3 (Turner et al., 2018, 1207 citations) demonstrated doubled progression-free survival compared to endocrine therapy alone. Over 8,000 citations across key trials establish these agents as standard of care.
Why It Matters
CDK4/6 inhibitors combined with letrozole or fulvestrant have doubled median progression-free survival to 24-27 months in first-line HR+/HER2- metastatic breast cancer, as shown in MONALEESA-7 (Slamon et al., 2019, 789 citations). MONARCH 2 trial established abemaciclib-fulvestrant's overall survival benefit (Sledge et al., 2019, 931 citations), influencing NCCN guidelines (Gradishar et al., 2020, 1606 citations) and ESO-ESMO consensus (Cardoso et al., 2020, 1282 citations). These therapies guide patient selection via biomarkers and reshape treatment sequencing in advanced disease.
Key Research Challenges
Resistance Mechanisms
Tumors develop resistance to CDK4/6 inhibitors via RB1 loss or cyclin E1 overexpression after 18-24 months. Turner et al. (2018, PALOMA-3) noted 20% RB1 alterations in resistant cases. Identifying early biomarkers remains critical (Ding et al., 2020).
Optimal Patient Selection
Lack of predictive biomarkers beyond HR+/HER2- status limits efficacy in heterogeneous populations. Hortobágyi et al. (2016, MONALEESA-2) showed uniform PFS benefit, but subgroups with visceral disease vary. Guidelines emphasize clinical factors (Gradishar et al., 2020).
Sequencing with Other Therapies
Unclear timing of CDK4/6 inhibitors versus PI3K inhibitors like alpelisib post-progression. SOLAR-1 trial (André et al., 2019, 2360 citations) highlights PIK3CA mutation testing after CDK4/6 failure. ESMO guidelines stress trial enrollment (Gennari et al., 2021).
Essential Papers
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · 2019 · New England Journal of Medicine · 2.4K citations
Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with <i>PIK3CA</i>-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine ther...
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · 2016 · New England Journal of Medicine · 1.9K citations
Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving r...
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham et al. · 2020 · Journal of the National Comprehensive Cancer Network · 1.6K citations
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the t...
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus et al. · 2020 · Annals of Oncology · 1.3K citations
Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased patholo...
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios et al. · 2021 · Annals of Oncology · 1.2K citations
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · 2018 · New England Journal of Medicine · 1.2K citations
Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer over...
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
George W. Sledge, Masakazu Toi, Patrick Neven et al. · 2019 · JAMA Oncology · 931 citations
ClinicalTrials.gov identifier: NCT02107703.
Reading Guide
Foundational Papers
Start with Hortobágyi et al. (2016, NEJM) for first-line ribociclib PFS (24.5 vs 12.8 mo), then Turner et al. (2018) for palbociclib OS confirmation; Ding et al. (2020) explains CDK mechanism.
Recent Advances
Slamon et al. (2019, MONALEESA-3 OS), Sledge et al. (2019, MONARCH 2 OS), Gradishar et al. (2020 NCCN) and Gennari et al. (2021 ESMO) for current standards.
Core Methods
Double-blind RCTs with PFS primary endpoint (RECIST), Kaplan-Meier survival, Cox HR; biomarkers via NGS for PIK3CA/RB1; GRADE high evidence from 5+ phase 3 trials.
How PapersFlow Helps You Research CDK4/6 Inhibitors in Hormone Receptor-Positive Breast Cancer
Discover & Search
Research Agent uses searchPapers to retrieve all 10 key papers on CDK4/6 inhibitors like 'Ribociclib as First-Line Therapy' (Hortobágyi et al., 2016), then citationGraph maps 8,000+ citations linking MONALEESA and PALOMA trials; exaSearch uncovers subgroup PFS data across guidelines.
Analyze & Verify
Analysis Agent employs readPaperContent on MONARCH 2 (Sledge et al., 2019) to extract hazard ratios, verifyResponse with CoVe checks survival claims against raw abstracts, and runPythonAnalysis computes meta-analysis of PFS from 5 trials using pandas; GRADE grading scores evidence as high for first-line ribociclib (Hortobágyi et al., 2016).
Synthesize & Write
Synthesis Agent detects gaps like post-CDK4/6 PI3K sequencing from SOLAR-1 (André et al., 2019), flags contradictions in resistance rates; Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations integrates 10 papers, latexCompile generates review PDFs with exportMermaid for PFS Kaplan-Meier diagrams.
Use Cases
"Meta-analyze PFS hazard ratios from palbociclib, ribociclib, abemaciclib phase 3 trials"
Research Agent → searchPapers (5 trials) → Analysis Agent → runPythonAnalysis (pandas forest plot of HRs 0.56-0.63) → Synthesis Agent → exportCsv of pooled HR 0.59 (95% CI 0.52-0.67).
"Draft LaTeX section comparing MONALEESA-3 OS to PALOMA-3"
Research Agent → citationGraph (Slamon 2019 + Turner 2018) → Writing Agent → latexEditText (table with 34 vs 28 mo OS) → latexSyncCitations → latexCompile → downloadable PDF.
"Find code for CDK4/6 resistance simulation models"
Research Agent → paperExtractUrls (Ding et al. 2020) → paperFindGithubRepo → githubRepoInspect (cell cycle ODE models) → runPythonAnalysis (NumPy simulation of cyclin E bypass).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ CDK4/6 papers: searchPapers → citationGraph → GRADE all trials → structured report ranking ribociclib OS evidence highest. DeepScan applies 7-step CoVe to verify PFS doubling claims across NCCN/ESMO guidelines with statistical checkpoints. Theorizer generates hypotheses on triplet therapy sequencing from MONALEESA/PALOMA gaps.
Frequently Asked Questions
What defines CDK4/6 inhibitors in HR+ breast cancer?
Selective CDK4/6 blockers like palbociclib, ribociclib, abemaciclib combined with letrozole or fulvestrant for HR+/HER2- advanced disease, blocking G1-S transition (Ding et al., 2020).
What methods prove their efficacy?
Phase 3 RCTs: MONALEESA-2 (ribociclib-letrozole, HR 0.56, Hortobágyi et al., 2016), PALOMA-3 (palbociclib-fulvestrant, OS 34.9 mo, Turner et al., 2018), MONARCH 2 (abemaciclib, Sledge et al., 2019).
What are key papers?
Top: Hortobágyi et al. (2016, 1897 cites, first-line ribociclib), Turner et al. (2018, 1207 cites, palbociclib OS), Sledge et al. (2019, 931 cites, abemaciclib OS); guidelines: Gradishar et al. (2020, NCCN).
What open problems exist?
Resistance biomarkers (RB1/cyclin E1), optimal sequencing with PI3K inhibitors (André et al., 2019 SOLAR-1), and frontline triplet combinations lack phase 3 data.
Research Advanced Breast Cancer Therapies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching CDK4/6 Inhibitors in Hormone Receptor-Positive Breast Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Advanced Breast Cancer Therapies Research Guide